#begin document (nw/wsj/01/wsj_0180); part 000
nw/wsj/01/wsj_0180   0    0         Genetics    NNP  (TOP(S(NP(NP*       -    -   -   -   (ORG*   (ARG0*            *   -
nw/wsj/01/wsj_0180   0    1        Institute    NNP              *       -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0    2             Inc.    NNP              *)      -    -   -   -       *)       *            *   -
nw/wsj/01/wsj_0180   0    3                ,      ,              *       -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0    4        Cambridge    NNP           (NP*       -    -   -   -    (GPE)       *            *   -
nw/wsj/01/wsj_0180   0    5                ,      ,              *       -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0    6            Mass.    NNP              *)      -    -   -   -    (GPE)       *            *   -
nw/wsj/01/wsj_0180   0    7                ,      ,              *)      -    -   -   -       *        *)           *   -
nw/wsj/01/wsj_0180   0    8             said    VBD           (VP*      say  01   -   -       *      (V*)           *   -
nw/wsj/01/wsj_0180   0    9               it    PRP    (SBAR(S(NP*)      -    -   -   -       *   (ARG1*       (ARG2*)  -
nw/wsj/01/wsj_0180   0   10              was    VBD           (VP*       -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   11          awarded    VBN           (VP*    award  01   1   -       *        *          (V*)  -
nw/wsj/01/wsj_0180   0   12             U.S.    NNP           (NP*       -    -   -   -    (GPE)       *       (ARG1*   -
nw/wsj/01/wsj_0180   0   13          patents    NNS              *)      -    -   -   -       *        *            *)  -
nw/wsj/01/wsj_0180   0   14              for     IN           (PP*       -    -   -   -       *        *   (ARGM-CAU*   -
nw/wsj/01/wsj_0180   0   15      Interleukin    NNP        (NP(NP*       -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   16               -    HYPH              *       -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   17               3      CD              *)      -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   18              and     CC              *       -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   19             bone     NN           (NP*       -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   20    morphogenetic     JJ              *       -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   21          protein     NN       *))))))))      -    -   -   -       *        *)           *)  -
nw/wsj/01/wsj_0180   0   22                .      .             *))      -    -   -   -       *        *            *   -

nw/wsj/01/wsj_0180   0    0            The     DT  (TOP(S(NP(NP*        -    -   -   -   *        *   (ARG2*        *            *   -
nw/wsj/01/wsj_0180   0    1         patent     NN              *)   patent  01   1   -   *      (V*)       *        *            *   -
nw/wsj/01/wsj_0180   0    2            for     IN           (PP*        -    -   -   -   *   (ARG1*        *        *            *   -
nw/wsj/01/wsj_0180   0    3    Interleukin    NNP           (NP*        -    -   -   -   *        *        *        *            *   -
nw/wsj/01/wsj_0180   0    4             -    HYPH              *        -    -   -   -   *        *        *        *            *   -
nw/wsj/01/wsj_0180   0    5             3      CD            *)))       -    -   -   -   *        *)       *)       *            *   -
nw/wsj/01/wsj_0180   0    6         covers    VBZ           (VP*     cover  01   -   -   *        *      (V*)       *            *   -
nw/wsj/01/wsj_0180   0    7      materials    NNS        (NP(NP*        -    -   -   -   *        *   (ARG1*   (ARG1*       (ARG2*   -
nw/wsj/01/wsj_0180   0    8            and     CC              *        -    -   -   -   *        *        *        *            *   -
nw/wsj/01/wsj_0180   0    9        methods    NNS              *)       -    -   -   -   *        *        *        *)           *)  -
nw/wsj/01/wsj_0180   0   10           used    VBN           (VP*       use  01   -   -   *        *        *      (V*)           *   -
nw/wsj/01/wsj_0180   0   11             to     TO         (S(VP*        -    -   -   -   *        *        *   (ARG2*            *   -
nw/wsj/01/wsj_0180   0   12           make     VB           (VP*      make  01   -   -   *        *        *        *          (V*)  -
nw/wsj/01/wsj_0180   0   13            the     DT           (NP*        -    -   -   -   *        *        *        *       (ARG1*   -
nw/wsj/01/wsj_0180   0   14          human     JJ      (NML(NML*        -    -   -   -   *        *        *        *            *   -
nw/wsj/01/wsj_0180   0   15          blood     NN              *        -    -   -   -   *        *        *        *            *   -
nw/wsj/01/wsj_0180   0   16           cell     NN              *)       -    -   -   -   *        *        *        *            *   -
nw/wsj/01/wsj_0180   0   17         growth     NN              *)       -    -   -   -   *        *        *        *            *   -
nw/wsj/01/wsj_0180   0   18         factor     NN              *)       -    -   -   -   *        *        *        *            *)  -
nw/wsj/01/wsj_0180   0   19            via     IN           (PP*        -    -   -   -   *        *        *        *   (ARGM-MNR*   -
nw/wsj/01/wsj_0180   0   20    recombinant     JJ       (NP(NML*        -    -   -   -   *        *        *        *            *   -
nw/wsj/01/wsj_0180   0   21            DNA    NNP              *)       -    -   -   -   *        *        *        *            *   -
nw/wsj/01/wsj_0180   0   22     technology     NN       *))))))))       -    -   -   -   *        *        *)       *)           *)  -
nw/wsj/01/wsj_0180   0   23              .      .             *))       -    -   -   -   *        *        *        *            *   -

nw/wsj/01/wsj_0180   0    0           Sandoz    NNP  (TOP(S(NP*         -    -   -   -   (ORG*   (ARG2*       (ARG0*   -
nw/wsj/01/wsj_0180   0    1             Ltd.    NNP           *)        -    -   -   -       *)       *)           *)  -
nw/wsj/01/wsj_0180   0    2              has    VBZ     (VP(VP*         -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0    3         licensed    VBN        (VP*    license  01   1   -       *      (V*)           *   -
nw/wsj/01/wsj_0180   0    4          certain     JJ     (NP(NP*         -    -   -   -       *   (ARG1*            *   -
nw/wsj/01/wsj_0180   0    5    manufacturing     NN       (NML*         -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0    6              and     CC           *         -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0    7        marketing     NN           *)        -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0    8           rights    NNS           *)        -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0    9              for     IN        (PP*         -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   10      Interleukin    NNP        (NP*         -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   11               -    HYPH           *         -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   12               3      CD         *)))        -    -   -   -       *        *)           *   -
nw/wsj/01/wsj_0180   0   13             from     IN        (PP*         -    -   -   -       *   (ARG0*            *   -
nw/wsj/01/wsj_0180   0   14         Genetics    NNP        (NP*         -    -   -   -   (ORG*        *            *   -
nw/wsj/01/wsj_0180   0   15        Institute    NNP        *))))        -    -   -   -       *)       *)           *   -
nw/wsj/01/wsj_0180   0   16              and     CC           *         -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   17               is    VBZ        (VP*         -    -   -   -       *        *            *   -
nw/wsj/01/wsj_0180   0   18       conducting    VBG        (VP*    conduct  01   -   -       *        *          (V*)  -
nw/wsj/01/wsj_0180   0   19      preclinical     JJ        (NP*         -    -   -   -       *        *       (ARG1*   -
nw/wsj/01/wsj_0180   0   20          studies    NNS           *)        -    -   -   -       *        *            *)  -
nw/wsj/01/wsj_0180   0   21             with     IN        (PP*         -    -   -   -       *        *   (ARGM-MNR*   -
nw/wsj/01/wsj_0180   0   22               it    PRP    (NP*)))))        -    -   -   -       *        *            *)  -
nw/wsj/01/wsj_0180   0   23                .      .          *))        -    -   -   -       *        *            *   -

nw/wsj/01/wsj_0180   0    0     Interleukin    NNP  (TOP(S(S(NP*           -    -   -   -       *        (ARG0*        *        *        *   -
nw/wsj/01/wsj_0180   0    1              -    HYPH             *           -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0    2              3      CD             *)          -    -   -   -       *             *)       *        *        *   -
nw/wsj/01/wsj_0180   0    3             may     MD          (VP*           -    -   -   -       *    (ARGM-MOD*)       *        *        *   -
nw/wsj/01/wsj_0180   0    4            help     VB          (VP*         help  01   -   -       *           (V*)       *        *        *   -
nw/wsj/01/wsj_0180   0    5              in     IN          (PP*           -    -   -   -       *        (ARG1*        *        *        *   -
nw/wsj/01/wsj_0180   0    6        treating    VBG        (S(VP*        treat  03   -   -       *             *      (V*)       *        *   -
nw/wsj/01/wsj_0180   0    7           blood     NN   (NP(NP(NML*           -    -   -   -       *             *   (ARG2*   (ARG1*        *   -
nw/wsj/01/wsj_0180   0    8            cell     NN             *)          -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0    9    deficiencies    NNS             *)          -    -   -   -       *             *        *        *)       *   -
nw/wsj/01/wsj_0180   0   10      associated    VBN          (VP*    associate  01   -   -       *             *        *      (V*)       *   -
nw/wsj/01/wsj_0180   0   11            with     IN          (PP*           -    -   -   -       *             *        *   (ARG2*        *   -
nw/wsj/01/wsj_0180   0   12          cancer     NN       (NP(NP*           -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   13       treatment     NN             *)          -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   14               ,      ,             *           -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   15            bone     NN      (NP(NML*           -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   16          marrow     NN             *)          -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   17     transplants    NNS             *)          -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   18             and     CC             *           -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   19           other     JJ          (NP*           -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   20           blood     NN         (NML*           -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   21              -    HYPH             *           -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   22            cell     NN             *)          -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   23       disorders    NNS   *)))))))))))          -    -   -   -       *             *)       *)       *)       *   -
nw/wsj/01/wsj_0180   0   24               ,      ,             *           -    -   -   -       *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   25        Genetics    NNP          (NP*           -    -   -   -   (ORG*             *        *        *   (ARG0*   -
nw/wsj/01/wsj_0180   0   26       Institute    NNP             *)          -    -   -   -       *)            *        *        *        *)  -
nw/wsj/01/wsj_0180   0   27            said    VBD          (VP*)         say  01   -   -       *             *        *        *      (V*)  -
nw/wsj/01/wsj_0180   0   28               .      .            *))          -    -   -   -       *             *        *        *        *   -

nw/wsj/01/wsj_0180   0    0              The     DT    (TOP(S(NP*           -    -   -   -           *             *   (ARG0*             *        *   -
nw/wsj/01/wsj_0180   0    1           second     JJ             *           -    -   -   -    (ORDINAL)   (ARGM-TMP*)       *             *        *   -
nw/wsj/01/wsj_0180   0    2           patent     NN             *)      patent  01   1   -           *           (V*)       *)            *        *   -
nw/wsj/01/wsj_0180   0    3        describes    VBZ          (VP*     describe  01   -   -           *             *      (V*)            *        *   -
nw/wsj/01/wsj_0180   0    4             bone     NN       (NP(NP*           -    -   -   -           *             *   (ARG1*             *        *   -
nw/wsj/01/wsj_0180   0    5    morphogenetic     JJ             *           -    -   -   -           *             *        *             *        *   -
nw/wsj/01/wsj_0180   0    6          protein     NN             *           -    -   -   -           *             *        *             *        *   -
nw/wsj/01/wsj_0180   0    7               -    HYPH             *           -    -   -   -           *             *        *             *        *   -
nw/wsj/01/wsj_0180   0    8               1      NN             *)          -    -   -   -           *             *        *             *        *   -
nw/wsj/01/wsj_0180   0    9                ,      ,             *           -    -   -   -           *             *        *             *        *   -
nw/wsj/01/wsj_0180   0   10                a     DT       (NP(NP*           -    -   -   -           *             *        *        (ARG0*        *   -
nw/wsj/01/wsj_0180   0   11        substance     NN             *)          -    -   -   -           *             *        *             *)       *   -
nw/wsj/01/wsj_0180   0   12             that    WDT   (SBAR(WHNP*)          -    -   -   -           *             *        *      (R-ARG0*)       *   -
nw/wsj/01/wsj_0180   0   13              can     MD        (S(VP*           -    -   -   -           *             *        *    (ARGM-MOD*)       *   -
nw/wsj/01/wsj_0180   0   14           induce     VB          (VP*       induce  01   1   -           *             *        *           (V*)       *   -
nw/wsj/01/wsj_0180   0   15        formation     NN       (NP(NP*)   formation  01   5   -           *             *        *        (ARG1*      (V*)  -
nw/wsj/01/wsj_0180   0   16               of     IN          (PP*           -    -   -   -           *             *        *             *   (ARG1*   -
nw/wsj/01/wsj_0180   0   17              new     JJ          (NP*           -    -   -   -           *             *        *             *        *   -
nw/wsj/01/wsj_0180   0   18        cartilage     NN    *))))))))))          -    -   -   -           *             *        *)            *)       *)  -
nw/wsj/01/wsj_0180   0   19                .      .            *))          -    -   -   -           *             *        *             *        *   -

nw/wsj/01/wsj_0180   0    0               The     DT     (TOP(S(S(NP*        -    -   -   -       *      *   (ARG2*        *        *   -
nw/wsj/01/wsj_0180   0    1            patent     NN                *)   patent  01   1   -       *    (V*)       *)       *        *   -
nw/wsj/01/wsj_0180   0    2            covers    VBZ             (VP*     cover  01   -   -       *      *      (V*)       *        *   -
nw/wsj/01/wsj_0180   0    3               BMP     NN  (NP(NP(NML(NML*        -    -   -   -       *      *   (ARG1*        *        *   -
nw/wsj/01/wsj_0180   0    4                -    HYPH                *        -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0    5                1      CD                *)       -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0    6              type     NN                *)       -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0    7          proteins    NNS                *)       -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0    8               and     CC                *        -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0    9    pharmaceutical     JJ          (NP(NP*        -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0   10      compositions    NNS                *        -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0   11               and     CC                *        -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0   12           methods    NNS                *)       -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0   13               for     IN             (PP*        -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0   14          treating    VBG           (S(VP*     treat  03   -   -       *      *        *      (V*)       *   -
nw/wsj/01/wsj_0180   0   15              bone     NN         (NP(NML*        -    -   -   -       *      *        *   (ARG2*        *   -
nw/wsj/01/wsj_0180   0   16                or     CC                *        -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0   17         cartilage     NN                *)       -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0   18           defects    NNS         *))))))))       -    -   -   -       *      *        *)       *)       *   -
nw/wsj/01/wsj_0180   0   19                 ,      ,                *        -    -   -   -       *      *        *        *        *   -
nw/wsj/01/wsj_0180   0   20          Genetics    NNP             (NP*        -    -   -   -   (ORG*      *        *        *   (ARG0*   -
nw/wsj/01/wsj_0180   0   21         Institute    NNP                *)       -    -   -   -       *)     *        *        *        *)  -
nw/wsj/01/wsj_0180   0   22              said    VBD             (VP*)      say  01   -   -       *      *        *        *      (V*)  -
nw/wsj/01/wsj_0180   0   23                 .      .               *))       -    -   -   -       *      *        *        *        *   -

nw/wsj/01/wsj_0180   0    0             The     DT  (TOP(S(S(NP*         -    -   -   -   *   (ARG0*          *        *        *         *   -
nw/wsj/01/wsj_0180   0    1         company     NN             *)        -    -   -   -   *        *)         *        *        *         *   -
nw/wsj/01/wsj_0180   0    2           added    VBD          (VP*        add  01   -   -   *      (V*)         *        *        *         *   -
nw/wsj/01/wsj_0180   0    3            that     IN        (SBAR*         -    -   -   -   *   (ARG1*          *        *        *         *   -
nw/wsj/01/wsj_0180   0    4              it    PRP        (S(NP*)        -    -   -   -   *        *     (ARG0*)       *        *         *   -
nw/wsj/01/wsj_0180   0    5             has    VBZ          (VP*         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0    6           filed    VBN          (VP*       file  01   -   -   *        *        (V*)       *        *         *   -
nw/wsj/01/wsj_0180   0    7          patent     NN          (NP*     patent   -   1   -   *        *     (ARG1*        *        *         *   -
nw/wsj/01/wsj_0180   0    8    applications    NNS             *)        -    -   -   -   *        *          *)       *        *         *   -
nw/wsj/01/wsj_0180   0    9              ``     ``             *         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   10              on     IN          (PP*         -    -   -   -   *        *   (C-ARG1*        *        *         *   -
nw/wsj/01/wsj_0180   0   11               a     DT       (NP(NP*         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   12           large     JJ             *         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   13          number     NN             *)        -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   14              of     IN          (PP*         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   15       different     JJ          (NP*         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   16             BMP     NN             *         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   17        proteins    NNS          *))))        -    -   -   -   *        *          *)       *        *         *   -
nw/wsj/01/wsj_0180   0   18              ''     ''        *))))))        -    -   -   -   *        *)         *        *        *         *   -
nw/wsj/01/wsj_0180   0   19             and     CC             *         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   20             the     DT     (S(NP(NP*         -    -   -   -   *        *          *        *   (ARG1*         *   -
nw/wsj/01/wsj_0180   0   21          patent     NN             *)    patent  01   1   -   *        *          *      (V*)       *         *   -
nw/wsj/01/wsj_0180   0   22              on     IN          (PP*         -    -   -   -   *        *          *   (ARG1*        *         *   -
nw/wsj/01/wsj_0180   0   23             BMP     NN          (NP*         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   24              -    HYPH             *         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   25              1      CD           *)))        -    -   -   -   *        *          *        *)       *)        *   -
nw/wsj/01/wsj_0180   0   26              is    VBZ          (VP*         be  01   -   -   *        *          *        *      (V*)        *   -
nw/wsj/01/wsj_0180   0   27             the     DT       (NP(NP*         -    -   -   -   *        *          *        *   (ARG2*    (ARG1*   -
nw/wsj/01/wsj_0180   0   28           first     JJ             *)        -    -   -   -   *        *          *        *        *         *)  -
nw/wsj/01/wsj_0180   0   29              it    PRP   (SBAR(S(NP*)        -    -   -   -   *        *          *        *        *    (ARG0*)  -
nw/wsj/01/wsj_0180   0   30             has    VBZ          (VP*         -    -   -   -   *        *          *        *        *         *   -
nw/wsj/01/wsj_0180   0   31        received    VBN    (VP*)))))))   receive  01   -   -   *        *          *        *        *)      (V*)  -
nw/wsj/01/wsj_0180   0   32               .      .            *))        -    -   -   -   *        *          *        *        *         *   -

nw/wsj/01/wsj_0180   0    0            BMP    NN   (TOP(S(S(NP*           -    -   -   -   *        (ARG1*   (ARG3*        *        *   -
nw/wsj/01/wsj_0180   0    1       products   NNS              *)          -    -   -   -   *             *)       *)       *        *   -
nw/wsj/01/wsj_0180   0    2            may    MD           (VP*           -    -   -   -   *    (ARGM-MOD*)       *        *        *   -
nw/wsj/01/wsj_0180   0    3             be    VB           (VP*           be  01   -   -   *           (V*)       *        *        *   -
nw/wsj/01/wsj_0180   0    4         useful    JJ         (ADJP*)          -    -   -   -   *        (ARG2*)       *        *        *   -
nw/wsj/01/wsj_0180   0    5             in    IN        (PP(PP*           -    -   -   -   *    (ARGM-LOC*        *        *        *   -
nw/wsj/01/wsj_0180   0    6       fracture    NN           (NP*           -    -   -   -   *             *        *        *        *   -
nw/wsj/01/wsj_0180   0    7        healing    NN             *))          -    -   -   -   *             *        *        *        *   -
nw/wsj/01/wsj_0180   0    8            and    CC              *           -    -   -   -   *             *        *        *        *   -
nw/wsj/01/wsj_0180   0    9             in    IN           (PP*           -    -   -   -   *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   10       treating   VBG         (S(VP*        treat  03   -   -   *             *      (V*)       *        *   -
nw/wsj/01/wsj_0180   0   11           bone    NN        (NP(NP*           -    -   -   -   *             *   (ARG2*   (ARG1*        *   -
nw/wsj/01/wsj_0180   0   12           loss    NN              *)          -    -   -   -   *             *        *        *)       *   -
nw/wsj/01/wsj_0180   0   13     associated   VBN           (VP*    associate  01   -   -   *             *        *      (V*)       *   -
nw/wsj/01/wsj_0180   0   14           with    IN           (PP*           -    -   -   -   *             *        *   (ARG2*        *   -
nw/wsj/01/wsj_0180   0   15    periodontal    JJ        (NP(NP*           -    -   -   -   *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   16        disease    NN              *)          -    -   -   -   *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   17            and    CC              *           -    -   -   -   *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   18        certain    JJ           (NP*           -    -   -   -   *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   19        cancers   NNS   *))))))))))))          -    -   -   -   *             *)       *)       *)       *   -
nw/wsj/01/wsj_0180   0   20              ,     ,              *           -    -   -   -   *             *        *        *        *   -
nw/wsj/01/wsj_0180   0   21            the    DT           (NP*           -    -   -   -   *             *        *        *   (ARG0*   -
nw/wsj/01/wsj_0180   0   22        company    NN              *)          -    -   -   -   *             *        *        *        *)  -
nw/wsj/01/wsj_0180   0   23           said   VBD           (VP*)         say  01   -   -   *             *        *        *      (V*)  -
nw/wsj/01/wsj_0180   0   24              .     .             *))          -    -   -   -   *             *        *        *        *   -

#end document
